| 5.44 0.08 (1.49%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.75 | 1-year : | 7.88 |
| Resists | First : | 5.78 | Second : | 6.75 |
| Pivot price | 4.74 |
|||
| Supports | First : | 4.4 | Second : | 3.55 |
| MAs | MA(5) : | 5.48 |
MA(20) : | 4.54 |
| MA(100) : | 4.13 |
MA(250) : | 3.98 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 79.9  |
D(3) : | 83.5 |
| RSI | RSI(14): 73.6 |
|||
| 52-week | High : | 5.78 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OBIO ] has closed below upper band by 18.0%. Bollinger Bands are 207.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.52 | 5.52 - 5.55 |
| Low: | 5.13 - 5.17 | 5.17 - 5.21 |
| Close: | 5.38 - 5.44 | 5.44 - 5.49 |
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Thu, 20 Aug 2026
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Wed, 19 Aug 2026
Insiders Buying Orchestra BioMed Holdings Might Wish They Invested More, Stock Gains 29% - Moomoo
Fri, 14 Aug 2026
Orchestra BioMed (OBIO) director uses 5,145 shares to cover RSU tax withholding - Stock Titan
Thu, 13 Aug 2026
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Mon, 10 Aug 2026
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - GlobeNewswire
Mon, 10 Aug 2026
Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.33, Implies 177% Upside - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 3.295e+007 (%) |
| Held by Institutions | 24.4 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.764e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -184.7 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 404.5 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 3.198e+007 % |
| Gross Profit (p.s.) | -179 |
| Sales Per Share | -794.6 |
| EBITDA (p.s.) | 6.364e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 8.5 |
| Dividend | 0 |
| Forward Dividend | 2.43e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|